Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ENTA market value is already below cash and you are predicting it will drop 10x below cash. When? Are you saying the pipeline has zero value?
The Street isn't giving much (if any) value to the pipeline. The $15/share price is reflective of only the 393M on hand cash which decreases on a monthly basis with the expected burn rate. With the sale of the royalties, the amount coming in from Abbvie isn't replacing and/or adding to the cash on hand. In summary, with each passing month, the on hand cash decreases and the stock price goes along with it. Correct me if I am wrong....?
Anyone have an educated guess as to the likelihood of a partner for 235 or 938? If low, what in the pipeline would keep this from being a $1-$3 stock?
There's no particular benefit to the accounting treatment; it's simply the proper way to handle a deferred liability under GAAP.
Thank you. Is the impetus for this accounting method tax efficiency?
Is it likely that the general market does not understand the accounting method being used, or is otherwise using this accounting method as an excuse to knock Enanta a little harder?
Does this accounting benefit Enanta through other mechanisms such as retaining eligibility for some government and oversight programs?
Thank you again!
On page 8 of the same 10-Q document, there’s a heading that says, “amounts in thousands, except per share data.” This header applies to all of the notes to the financial statements that follow, so the “$200,000” in the excerpt I posted means $200 million.
Re: Accounting treatment of the Omers transaction
Here’s the explanation from ENTA’s FY3Q23 10-Q (p.12):
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001177648/000095017023039754/enta-20230630.htm
I would like to propose a benefit of the doubt for the poor performing stock and attribute the decline in price to an expectation of the masses that the entire market is going to decline.
This poor stock is taking the hit upfront because it is strictly a provider of research and development.
I do not understand the accounting methods for the sale of a portion of the HCV revenue. I do understand the terms of the agreement, I do not understand the accounting practice, i.e., recording it as debt.
Please correct me if I am wrong and I am thankful for any explanation that can be provided.
Like you know me.
Good humor
10 out of 10.
I made a song and dance about it. I admit.
Still nothing informative.
Well, I am not sure if you read it or not.
Firstly, what I said is not Paxlovid has better data than EDP-235.
In fact, I was asking from what perspective EDP-235 is better
Secondly, I understand EDP-235, 938, 514, 323 are the names of inhibitors. I am not entirely sure if people call them a pipeline or not. I thought we call them a pipeline.
If I were wrong, you could say in detail.
Not just blaming. I think you should study how to speak to people. The way you use is so violent and rude. I am not sure whether it derives from your arrogance or pride or whatever.
I have never said you've told me the wrong 2Q revenue. You just ignore what you wrongly thought.
I am sensitive. YES. Because I try to think and understand others' perspectives. Not like you.
IMHO, someone who has better sympathy is a better person.
I can not get any informative information from your writing.
I will end discuss with you. It is hard to say this is a discussion, though. Bye. Enjoy your smart investment.
Oh I see. That makes sense :)
Thank you.
The most recent quarter was fiscal Q3 because ENTA's fiscal years run from Oct 1 to Sep 30 (#msg-172537414).
Mother of god!
I know it is the 2Q conference call.
THE REASON I write Q3 is the company use that term. Go to the website or go to Seeking alpha, and you could easily find it. I don't know why they write down Q3 but it says so. I thought you must go to enanta's homepage or something. But I was wrong.
What kind of person are you making me.
I listened conference call and watched the slides
How do you think I know the name of company's pipeline.
'Waste water'wise
I couldn't find it in google yet because it needs context of this company.
I know it is not that great to ask everything
But I studied this company 7hours yesterday. And I will study more for a while.
But no worries at least I will find it finally at some point.
I do not know how long you followed Enanta.
And I don't know how well educated you are.
But this attitude is not that nice of you as a person.
You could just say what it is.
You DO NOT HAVE TO BUT.
And there is someone who claim about Paxlovid's 2Q revenue. You can easily find him
That person is Not You though
You did NOT say about Q2's Paxlovid revenue.
Please Think before you write.
I see. You think it is still a big opportunity for ENTA, don't you? I understand it. Compared to its Market Cap. it is huge, isn't it?
What I meant about transition is PFE says one of the reasons for poor revenue on Paxlovid is they are changing their method of sales to commercial markets rather than to government deals. That's what I understood from their recent conference call. I was asking you guys' opinion on it. Whether it would be better for PFE's Paxlovid sales or not.
Thank you for your elaboration. I mean it.
I've seen the data of EDP-235 and it has more steep data than Paxlovid. But I am not a doctor, and I don't exactly know how much it has more powerful efficacy than Paxlovid. I hope it is way better for lots of patients and us. That was the reason I posted it. Whoever saw the graph would know that simple information. Don't be mad. I apologize for my poor knowledge. I am just an investor who is trying to grasp about this company for my future investment.
Anyway, I've listened about the 'waste water' in 3Q C.C. of Enanta. Do you happen to know where to see the data of it?
and when did I say something wrong about Paxlovid sales? I've only asked about 23.2Q. revenue. Isn't it 143m? I've seen it on 10Q, sec.gov.
I see, thank you. But the guidance is still less than last year, like 1 of 3. Do you think the transition to traditional commercial markets is better for Paxlovid's revenue? Care to elaborate?
I have heard of the seasonality of them and I have seen cases of covid-19 spike. But when you go to CDC and see the data of patients, which is not that many. Look at 2022 2Q revenue. Don't you think it is almost the end of covid?
What are you talking about? Are you sure it is 1.49b? Is U.S. revenue like 1.39m?
PFE says 2Q23 is a nadir, as explained in #msg-172488867.
More like 1.49 Billion in Q2.
Have you seen the 2Q revenue of Paxlovid, Pfizer? It is 143m. Do you think covid is over or it is just because of the cycle?
AVIR modifies phase-3 protocol for COVID antiviral, bemnifosbuvir:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172556375
Yes, I will post ENTA's pro forma net cash after I have studied the 2Q23 10-Q, which was filed this afternoon.
"Cash" means actual bank-account cash or cash-equivalent securities such as money-market funds and Treasury bills. ENTA is not in the investment business.
I understand that ENTA's cash may carry them for a little while, but what do they do with their stash; Is it invested in US Treasuries? Can the company do anything with the money that the board approves, what options does a company like ENTA have for investing cash?
Listen again. They said they have to talk to regulators first. You don’t have the facts straight
Which company do you think would be the partner for SPRINT? Was there any discussion on it? I mean, I could not find it yet.
And what is the most important factor to substitute Paxlovid when it is approved? I guess it would be the absence of ritonavir. Do you agree with this? By the looks of the data, it doesn't show strong potency compared to Paxlovid.
They repeated many times that their regulatory path is through a partnership (they’ve done it with ABBV before for HCV). ENTA definitely doesn’t have a bandwidth to run multi-thousand-patient global Phase III studies
That job ad you caught a few weeks ago makes more sense in light of the disclosure on today’s CC that ENTA has initiated discovery work in an undisclosed non-virology area.
On today’s call, there was an admission that there was no regulatory path for the Covid drug. This is pretty disappointing.
Massive cash burn on HMPV. What’s the point?
Combination treatment for RSV remains a possibility, as discussed on today's CC.
I suppose that, theoretically, fusion inhibitors should be better for prophylaxis and N-inhibitors for treatment. However, other properties such as potency, safety, and PK might be more important. It's likely that, as with HIV and HCV, a combination of compounds with different modes of action would have significant synergy."
ENTA FY3Q23* financials—6/30/23_cash=$393M:
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-36
FY3Q23 royalty revenue was $18.9M.†
FY3Q23 R&D expenses were $43.0M, consistent with the quarterly run rate of ENTA’s updated FY2023 guidance of $165-175M.
FY3Q23 SG&A expenses were $12.6M, consistent with the quarterly run rate of ENTA’s updated FY2023 guidance of $50-55M.
†ENTA’s partial sale of Mavyret royalties took effect on 7/1/23, so it did not affect the FY3Q23 income statement.
*ENTA’s fiscal years end on September 30.
Fusion inhibitors are not effective once the virus has entered a particular cell. N inhibitors, on the other hand, impede viral replication inside an infected cell.
Is there anyone who knows if N inhibitor is better than Fusion inhibitor in RSV?
The NIH is running trials to assess therapies that might help combat long Covid. I guess Jake should tell the NIH they don't know what they are doing.
Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023:
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-host-conference-call-august-7-430-pm-et-1
Followers
|
98
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
3309
|
Created
|
03/20/13
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |